4-(3,5-dimethylpiperidin-1-yl)phenylamine | 85984-25-4

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 英文名称: 4-(3,5-dimethylpiperidin-1-yl)phenylamine
• 英文别名: 4-(3,5-Dimethylpiperidin-1-yl)aniline
• CAS: 85984-25-4
• 化学式: C₁₃H₂₀N₂
• 分子量: 204.315
• InChiKey: OASMPJKZOCFNCC-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.1
• 重原子数：
  15
• 可旋转键数：
  1
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.54
• 拓扑面积：
  29.3
• 氢给体数：
  1
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  4-(3,5-dimethylpiperidin-1-yl)phenylamine 、 2,4-二氯-5-三氟甲基嘧啶 在 三乙胺 、 zinc(II) chloride 作用下， 以 乙醚 、 二氯甲烷 、 叔丁醇 为溶剂， 反应 5.0h， 以84%的产率得到4-Chloro-N-(4-(3,5-dimethylpiperidin-1-yl)phenyl)-5-(trifluoromethyl)pyrimidin-2-amine
  参考文献：
  名称：

  Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors

  摘要：

  Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[ 3,2-c] pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.10.011

文献信息

• Aminoalkyl-substituted aromatic bicyclic compounds, methods for their preparation and their use as pharmaceuticals
  申请人：——

  公开号：US20030212070A1

  公开（公告）日：2003-11-13

  The present invention relates to aminoalkyl-substituted aromatic bicyclic compounds of formula I, 1 which are valuable pharmaceutically active compounds that are suitable, for example, for the treatment of obesity, type II diabetes, arteriosclerosis, high blood pressure, paresthesia, depression, anxiety, anxiety neuroses, schizophrenia, disorders associated with the circadian rhythm, and drug abuse, as well as normalizing lipid metabolism.

  本发明涉及公式I的氨基烷基取代芳香双环化合物，这些化合物是有价值的药用活性化合物，例如适用于治疗肥胖症、2型糖尿病、动脉硬化、高血压、感觉异常、抑郁症、焦虑症、焦虑神经症、精神分裂症、与昼夜节律相关的疾病以及药物滥用，同时还能正常化脂质代谢。
• NPYY5 ANTAGONISTS
  申请人：SHIONOGI & CO., LTD.

  公开号：EP1249233B9

  公开（公告）日：2009-08-05
• AMINOALKYL SUBSTITUIERTE AROMATISCHE BICYCLEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL
  申请人：Aventis Pharma Deutschland GmbH

  公开号：EP1418906A1

  公开（公告）日：2004-05-19
• [DE] AMINOALKYL SUBSTITUIERTE AROMATISCHE BICYCLEN, VERFAHREN ZU IHRER HERSTELLUNG UND IHRE VERWENDUNG ALS ARZNEIMITTEL<br/>[EN] AMINOALKYL-SUBSTITUTED AROMATIC BICYCLIC COMPOUNDS, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICAMENTS<br/>[FR] COMPOSES BICYCLIQUES AROMATIQUES A SUBSTITUTION AMINOALKYLE, PROCEDES DE PRODUCTION DE CES COMPOSES ET LEUR UTILISATION EN TANT QUE MEDICAMENTS
  申请人：AVENTIS PHARMA GMBH

  公开号：WO2003015769A1

  公开（公告）日：2003-02-27

  Die Erfindung betrifft Aminoalkyl substituierte aromatische Bicyclen sowie deren physiologisch verträgliche Salze und physiologisch funktionelle Derivate. Es werden Verbindungen der Formel (I), worin die Reste die angegebenen Bedeutungen haben, sowie deren physiologisch verträglichen Salze und Verfahren zu deren Herstellung beschrieben. Die Verbindungen eignen sich z.B. als Anorektika.
• Identification of 4-(2-furanyl)pyrimidin-2-amines as Janus kinase 2 inhibitors
  作者：Yazhou Wang、Wei Huang、Minhang Xin、Pan Chen、Li Gui、Xinge Zhao、Feng Tang、Jia Wang、Fei Liu

  DOI：10.1016/j.bmc.2016.10.011

  日期：2017.1

  Janus kinases inhibitor is considered to have therapeutic potential for the treatment of oncology and immune-inflammatory diseases. Two series of 4-(2-benzofuranyl)pyrimidin-2-amine and 4-(4,5,6,7-tetrahydrofuro[3,2-c]pyridin-2-yl)pyrimidin-2-amine derivatives have been designed and synthesized. Primary SAR studies resulted in the discovery of a novel class of 4,5,6,7-tetrahydrofuro[ 3,2-c] pyridine based JAK2 inhibitors with higher potency (IC50 of 0.7 nM) and selectivity (>30 fold) to JAK3 kinase than tofacitinib. (C) 2016 Elsevier Ltd. All rights reserved.